IDEXX Laboratories, Inc. vs Vertiv Holdings Co — how do they compare? IDEXX Laboratories, Inc. trades at $518.41 (market cap $40.43B), while Vertiv Holdings Co trades at $243.25 (market cap $93.83B). The key difference: Vertiv Holdings Co is far larger — about 2.3× IDEXX Laboratories, Inc.'s market cap, and Vertiv Holdings Co pays a 0.1% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Vertiv Holdings Co for 39 Days on average.
| IDXX | VRT | |
|---|---|---|
Market Cap | $40.43B | $93.83B |
Volume | 692,164 | 5,855,911 |
Sector | Health | Industrials |
52-Week High | $766.68 | $376.23 |
52-Week Low | $504.70 | $149.83 |
Typical Hold Time | 46 Days | 39 Days |
Enterprise Value | $41.32B | $94.06B |
Dividend Yield | — | 0.1% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Vertiv (VRT) trades at $244.75, down 0.71% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $1.52 versus $1.42 expected, and robust profitability with a net income margin of 15.09% and ROE of 43.94%. Revenue growth is projected to increase from $10.23B in 2025 to $11.5B in 2026. Analyst sentiment remains overwhelmingly positive with a 95.24% buy rating and a consensus price target of $364.94, highlighting confidence in VRT's position in the AI data center infrastructure market.
The outlook for VRT is bullish based on strong earnings momentum and AI-driven demand for data center solutions, though high valuation ratios (P/E of 55.14) and a recent legal investigation pose risks. The stock offers significant upside to the consensus target, but investors should monitor competitive pressures and execution on growth forecasts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →